ERAS: erasca.com Price/Earnings to Growth Multiple
Erasca, Inc. (ERAS) is currently undergoing early-stage inhibitor trials, which creates high venture risks prior to market entry. The business is based on developing precision medicines to block mutations in the RAS/MAPK pathway. The PEG ratio trajectory confirms the current valuation, where 0.00 represents the latest metric reading. The company's success relies on therapeutic precision and future contracts with pharma behemoths.
Analytical breakdowns for Erasca, Inc. (ERAS)
- share price and consensus valuation forecast:
- market capitalization information:
- book value of equity indicators:
- business debt structure and liquidity details:
- company profitability and valuation multiples indicators:
ERAS - Net Profit|Future Profit Erasca, Inc.|ERAS - P/E Multiple|Forward P/E Multiple Erasca Oncology|ERAS - Price/Earnings to Growth Multiple|Business Value to Operating Income Before Depreciation Erasca Corp|ERAS - Operating profit EBITDA|Net earnings per share for the last four quarters Erasca|ERAS - Earnings per share for the last twelve months|Year-over-year earnings per share growth for the last 12 months erasca.com|ERAS - Earnings growth in current year|Expected earnings per share growth for next year Erasca, Inc.
Fundamental company analysis:Erasca Inc, ERAS
Analyzing the PEG ratio allows for an assessment of Erasca, Inc. (ERAS) as a science-driven biotech company that minimizes capital expenditures through the outsourcing of production and research. This indicator compares the stock's market value with earnings growth rates, where a value below one signals that the asset is undervalued relative to its expansion, making it possible to identify potentially high-growth companies.
Competing companies
ONC (BeiGene Ltd.) - Growth-Adjusted Payback Ratio|PEG Multiple HALO (Halozyme Inc.)|RVMD - Price/Earnings to Growth Multiple|AAPG: Price/Earnings to Growth Multiple|CGON - PEG Multiple|UroGen Pharma (URGN) - Price/Earnings to Growth Ratio|Bicara Therapeutics Inc - Growth-Adjusted Payback Ratio|PSNL (Personalis Corp) - PEG Multiple|Price to Earnings Adjusted for Growth Rate Delcath Corp DCTH|PEG Multiple YMAB|AURA - Price to Earnings Adjusted for Growth Rate|Price/Earnings to Growth Ratio Candel Therapeutics, Inc. CADL|Growth-Adjusted Payback Ratio ARAY|SELLAS Life Sciences Group Inc. - PEG Multiple|ACTU - PEG Multiple|Citius Oncology, Inc. (CTOR) - Price/Earnings to Growth Ratio|HURA - Growth-Adjusted Market Cap to Net Income|TARA (Protara Therapeutics, Inc.) - PEG Multiple|Price/Earnings to Growth Multiple Fate Therapeutics Inc (FATE)|PEG Multiple WHWK|PEG Multiple tscan.com (TCRX)|Champions Oncology, Inc. - Price/Earnings to Growth Multiple|Growth-Adjusted Payback Ratio XBIT|CEL-SCI Corp - PEG Multiple|Growth-Adjusted Market Cap to Net Income OS Therapies Inc. OSTX|Radiopharm Theranostics Limited (RADX) - Price/Earnings to Growth Ratio|Growth-Adjusted P/E Ratio ARTV|ANL (Adlai Nortye Ltd) - PEG Multiple|Price/Earnings to Growth Multiple verupharma.com (VERU)|Price/Earnings to Growth Multiple TPST (Tempest Therapeutics, Inc.)|Growth-Adjusted Market Cap to Net Income xiliotx.com|PEG Multiple RENB (Renovaro)|Mural Oncology PLC (MURA) - Price to Earnings Adjusted for Growth Rate|KAPA - Price/Earnings to Growth Ratio|Growth-Adjusted Payback Ratio OKUR (OnKure Therapeutics Inc)|GDTC: PEG Multiple|Curis (CRIS) - PEG Multiple|Price/Earnings to Growth Ratio Apollomics Inc.|Tharimmune Corporation (THAR) - Growth-Adjusted Market Cap to Net Income|PEG Multiple ADVB|Price/Earnings to Growth Multiple genprex.com GNPX|PEG Multiple CLDI (Calidi Biotherapeutics, Inc.)|PEG Multiple Sunshine Biopharma Inc. SBFM|XBIO - Price/Earnings to Growth Ratio|SLRX (Salarius Pharma) - Growth-Adjusted P/E Ratio|PPBT: PEG Multiple|Price/Earnings to Growth Multiple American Oncology Network, Inc.|BGNE (BeiGene) - PEG Multiple|Price to Earnings Adjusted for Growth Rate Checkpoint Therapeutics Inc. CKPT|Price/Earnings to Growth Ratio Elevation Oncology, Inc. (ELEV)|ICAD (icadmed.com) - Growth-Adjusted Payback Ratio|Ikena Oncology - Price/Earnings to Growth Multiple|Growth-Adjusted Payback Ratio NTBL|Viracta - PEG Multiple|MorphoSys Inc (MOR) - Price/Earnings to Growth Multiple|NAYA (NAYA Bio) - Price/Earnings to Growth Multiple|Ascentage (AAPGV) - PEG Multiple
